«Past HIV
vaccine trials reveal new path to success.»
Not exact matches
After phase III
trials, reported in 2006, ended in disappointment for the prostate cancer
vaccine Provenge (made by Dendreon in Seattle), subsequent analyses
revealed that men whose prostate cancer had spread survived a median of 4.5 months longer than those given a placebo.
And scientists who conduct human challenge studies, which typically involve a few dozen participants, say they have critical benefits: In addition to saving time and money, they can
reveal harm caused by a potential drug or
vaccine before it enters large - scale human efficacy
trials.
One problem
revealed by the
trial was that only 38 percent of vaccinated subjects developed high levels of antibodies against the drug; Kosten is working to increase the
vaccine's antibody generation.
Antibody action Only an efficacy
trial involving people at risk of infection can
reveal whether a
vaccine prevents infection.
Results from the first Ebola
vaccine clinical
trial conducted in Africa (in 2009 - 2010)
reveal a
vaccine candidate produces the same immune response seen in the United States in an African setting.